The SOMAscan assay has an advantage over immunoassay-based methods because it measures a large number of proteins in a cost-effective manner. However, the performance of this technology compared to the routinely used immunoassay techniques needs to be evaluated.
Objective:
We performed comparative analyses of SOMAscan and immunoassay-based protein measurements for five cerebrospinal fluid (CSF) proteins associated with Alzheimer’s disease (AD) and neurodegeneration: NfL, Neurogranin, sTREM2, VILIP-1, and SNAP-25.
Methods:
We compared biomarkers measured in ADNI (N = 689), Knight-ADRC (N = 870), DIAN (N = 115), and Barcelona-1 (N = 92) cohorts. Raw protein values were transformed using z-score in order to combine measures from the different studies. sTREM2 and VILIP-1 had more than one analyte in SOMAscan; all available analytes were evaluated. Pearson’s correlation coefficients between SOMAscan and immunoassays were calculated. Receiver operating characteristic curve and area under the curve were used to compare prediction accuracy of these biomarkers between the two platforms.
Results:
Neurogranin, VILIP-1, and NfL showed high correlation between SOMAscan and immunoassay measures (r > 0.9). sTREM2 had a fair correlation (r > 0.6), whereas SNAP-25 showed weak correlation (r = 0.06). Measures in both platforms provided similar predicted performance for all biomarkers except SNAP-25 and one of the sTREM2 analytes. sTREM2 showed higher AUC for SOMAscan based measures.
Conclusion:
Our data indicate that SOMAscan performs as well as immunoassay approaches for NfL, Neurogranin, VILIP-1, and sTREM2. Our study shows promise for using SOMAscan as an alternative to traditional immunoassay-based measures. Follow-up investigation will be required for SNAP-25 and additional established biomarkers.
YalowRS, BersonSA (1960) Immunoassay of endogenous plasma insulin in man. J Clin Invest39, 1157–1175.
2.
EngvallE, PerlmannP (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry8, 871–874.
3.
DarwishIA (2006) Immunoassay methods and their applications in pharmaceutical analysis: Basic methodology and recent advances. Int J Biomed Sci2, 217–235.
4.
SakamotoS, PutalunW, VimolmangkangS, PhoolcharoenW, ShoyamaY, TanakaH, MorimotoS (2018) Enzyme-linked immunosorbent assay for the quantitative/qualitative analysis of plant secondary metabolites. J Nat Med72, 32–42.
5.
HoofnagleAN, WenerMH (2009) The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods347, 3–11.
TinA, YuB, MaJ, MasushitaK, DayaN, HoogeveenRC, BallantyneCM, CouperD, RebholzCM, GramsME, AlonsoA, MosleyT, HeissG, GanzP, SelvinE, BoerwinkleE, CoreshJ (2018) Reproducibility and variability of protein analytes measured using a multiplexed modified aptamer assay. J Appl Lab Med4, 30–39.
10.
CandiaJ, CheungF, KotliarovY, FantoniG, SellersB, GriesmanT, HuangJ, StuccioS, ZingoneA, RyanBM, TsangJS, BiancottoA (2017) Assessment of variability in the SOMAscan assay. Sci Rep7, 14248.
11.
KukovaLZ, MansourSG, CocaSG, de FontnouvelleCA, Thiessen-PhilbrookHR, ShlipakMG, El-KhouryJM, ParikhCR (2019) Comparison of urine and plasma biomarker concentrations measured by aptamer-based versus immunoassay methods in cardiac surgery patients. J Appl Lab Med4, 331–342.
PiccioL, BuonsantiC, CellaM, TassiI, SchmidtRE, FenoglioC, RinkerJ, NaismithRT, Panina-BordignonP, PassiniN, GalimbertiD, ScarpiniE, ColonnaM, CrossAH (2008) Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain131, 3081–3091.
14.
EwersM, BiecheleG, Suárez-CalvetM, SacherC, BlumeT, Morenas-RodriguezE, DemingY, PiccioL, CruchagaC, KleinbergerG, ShawL, TrojanowskiJQ, HermsJ, DichgansM, BrendelM, HaassC, FranzmeierN (2020) Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med12, e12308.
15.
EwersM, FranzmeierN, Suárez-CalvetM, Morenas-RodriguezE, CaballeroMAA, KleinbergerG, PiccioL, CruchagaC, DemingY, DichgansM, TrojanowskiJQ, ShawLM, WeinerMW, HaassC; Alzheimer’s Disease Neuroimaging Initiative (2019) Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease. Sci Transl Med11, eaav6221.
BrinkmalmA, BrinkmalmG, HonerWG, FrölichL, HausnerL, MinthonL, HanssonO, WallinA, ZetterbergH, BlennowK, ÖhrfeltA (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener9, 53.
18.
CaoL, WangF, YangQG, JiangW, WangC, ChenYP, ChenGH (2012) Reduced thyroid hormones with increased hippocampal SNAP-25 and Munc18-1 might involve cognitive impairment during aging. Behav Brain Res229, 131–137.
19.
TarawnehR, D’AngeloG, MacYE, XiongC, CarterD, CairnsNJ, FaganAM, HeadD, MintunMA, LadensonJH, LeeJM, MorrisJC, HoltzmanDM (2011) Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol70, 274–285.
20.
KesterMI, TeunissenCE, SutphenC, HerriesEM, LadensonJH, XiongC, ScheltensP, van der FlierWM, MorrisJC, HoltzmanDM, FaganAM (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther7, 59.
21.
ÁlvarezI, Diez-FairenM, AguilarM, GonzálezJM, YsamatM, TartariJP, CarcelM, AlonsoA, BrixB, ArendtP, PastorP (2021) Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol28, 1142–1152.
22.
(2012) SOMAscan® v4 Data Standardization and File Specification Technical Note.
23.
ArmbrusterDA, PryT (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev29,S49–S52.
24.
MeekerKL, ButtOH, GordonBA, FaganAM, SchindlerSE, MorrisJC, BenzingerTLS, AncesBM (2022) Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiol Dis166, 105662.
25.
HensonRL, DoranE, ChristianBT, HandenBL, KlunkWE, LaiF, LeeJH, RosasHD, SchupfN, ZamanSH, LottIT, FaganAM (2020) Cerebrospinal fluid biomarkers of Alzheimer’s disease in a cohort of adults with Down syndrome. Alzheimers Dement (Amst)12, e12057.
26.
ZetterbergH, SkillbäckT, MattssonN, TrojanowskiJQ, PorteliusE, ShawLM, WeinerMW, BlennowK (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol73, 60–67.
27.
KesterMI, TeunissenCE, CrimminsDL, HerriesEM, LadensonJH, ScheltensP, van der FlierWM, MorrisJC, HoltzmanDM, FaganAM, AuthorC (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease original investigation. JAMA Neurol72, 1275–1280.
SuhreK, ArnoldM, BhagwatAM, CottonRJ, EngelkeR, RafflerJ, SarwathH, TharejaG, WahlA, DelisleRK, GoldL, PezerM, LaucG, SelimMAED, Mook-KanamoriDO, Al-DousEK, MohamoudYA, MalekJ, StrauchK, GrallertH, PetersA, KastenmüllerG, GiegerC, GraumannJ (2017) Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun8, 14357.
38.
LiuRX, Thiessen-PhilbrookHR, VasanRS, CoreshJ, GanzP, BonventreJV, KimmelPL, ParikhCR (2021) Comparison of proteomic methods in evaluating biomarker-AKI associations in cardiac surgery patients. Transl Res238, 49–62.
39.
BegcevicI, BrincD, DrabovichAP, BatruchI, DiamandisEP (2016) Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas. Clin Proteomics13, 11.
40.
KroksveenAC, OpsahlJA, AyeTT, UlvikRJ, BervenFS (2011) Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics74, 371–388.
41.
DemingY, LiZ, KapoorM, HarariO, Del-AguilaJL, BlackK, CarrellD, CaiY, FernandezMV, BuddeJ, MaS, SaefB, HowellsB, HuangK lin, BertelsenS, FaganAM, HoltzmanDM, MorrisJC, KimS, SaykinAJ, de JagerPL, AlbertM, MoghekarA, O’BrienR, RiemenschneiderM, PetersenRC, BlennowK, ZetterbergH, MinthonL, van DeerlinVM, LeeVMY, ShawLM, TrojanowskiJQ, SchellenbergG, HainesJL, MayeuxR, Pericak-VanceMA, FarrerLA, PeskindER, LiG, di NarzoAF, KauweJSK, GoateAM, CruchagaC (2017) Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers. Acta Neuropathol133, 839–856.
42.
AliM, SungYJ, WangF, FernándezMV, MorrisJC, FaganAM, BlennowK, ZetterbergH, HeslegraveA, JohanssonPM, SvenssonJ, NellgårdB, LleoA, AlcoleaD, ClarimonJ, RamiL, MolinuevoJL, Suárez-CalvetM, Morenas-RodríguezE, KleinbergerG, HaassC, EwersM, LevinJ, FarlowMR, PerrinRJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN); Dominantly Inherited Alzheimer Network (DIAN), CruchagaC (2022) Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS One17, e0267298.
